Fibroblast growth factor 23 inhibits osteogenic differentiation and mineralization of chicken bone marrow mesenchymal stem cells

Lyu, Zhengtian; Li, Haifang; Li, Xin; Wang, Hui; Jiao, Hongchao; Wang, Xiaojuan; Zhao, Jingpeng

doi:10.1016/j.psj.2022.102287

Cited by 4 publications

(2 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Choudhary et al has reported that 10 nM of PTH increased mineralization in vitro using marrow stromal cell (MSC) and calvarial osteoblast (COB) cultures from COX-2 knockout (KO) and wild type (WT) mice, as well as inhibiting SOST mRNA expression [30]. 10 nM PTH was also the lowest concentration of PTH found to inhibit the transcription of FGF23 in chicken bone marrow mesenchymal stem cells in vitro by Lyu et al [31].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rescue of High Glucose Impairment of Cultured Human Osteoblasts Using Cinacalcet and Parathyroid Hormone

et al. 2023

View full text Add to dashboard Cite

Patients with type 2 diabetes mellitus (T2DM) experience a higher risk of fractures despite paradoxically exhibiting normal to high bone mineral density (BMD). This has drawn into question the applicability to T2DM of conventional fracture reduction treatments that aim to retain BMD. In a primary human osteoblast culture system, high glucose levels (25 mM) impaired cell proliferation and matrix mineralization compared to physiological glucose levels (5 mM). Treatment with parathyroid hormone (PTH, 10 nM), a bone anabolic agent, and cinacalcet (CN, 1 µM), a calcimimetic able to target the Ca2+-sensing receptor (CaSR), were tested for their effects on proliferation and differentiation. Strikingly, CN+PTH co-treatment was shown to promote cell growth and matrix mineralization under both physiological and high glucose conditions. CN+PTH reduced apoptosis by 0.9-fold/0.4-fold as measured by Caspase-3 activity assay, increased alkaline phosphatase (ALP) expression by 1.5-fold/twofold, increased the ratio of nuclear factor κ-B ligand (RANKL) to osteoprotegerin (OPG) by 2.1-fold/1.6-fold, and increased CaSR expression by 1.7-fold/4.6-fold (physiological glucose/high glucose). Collectively, these findings indicate a potential for CN+PTH combination therapy as a method to ameliorate the negative impact of chronic high blood glucose on bone remodeling.

show abstract

Section: Introductionmentioning

confidence: 99%

“…10 nM PTH was also the lowest concentration of PTH found to inhibit the transcription of FGF23 in chicken bone marrow mesenchymal stem cells in vitro by Lyu et al . [ 31 ] .…”

Section: Introductionmentioning

confidence: 99%